TY - JOUR
T1 - Increased MR-guided high intensity focused ultrasound (MR-HIFU) sonication efficiency of uterine fibroids after carbetocin administration
AU - Anneveldt, Kimberley J
AU - van 't Oever, Heleen J
AU - Verpalen, Inez M
AU - Nijholt, Ingrid M
AU - Bartels, Wilbert
AU - Dijkstra, Jeroen R
AU - van den Hoed, Rolf D
AU - van 't Veer-Ten Kate, Miranda
AU - de Boer, Erwin
AU - Veersema, Sebastiaan
AU - Huirne, Judith A F
AU - Schutte, Joke M
AU - Boomsma, Martijn F
N1 - Funding Information:
This research was made possible with financial support from the Innovation and Science fund of Isala Hospital Zwolle , the Netherlands.
Publisher Copyright:
© 2022 The Authors
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Purpose: We investigated whether administration of the long-acting uterus stimulant carbetocin increased intra-subject sonication efficiency during Magnetic Resonance image guided High Intensity Focused Ultrasound (MR-HIFU) treatment of uterine fibroids.Method: In this prospective cohort study, thirty women with symptomatic uterine fibroids undergoing MR-HIFU treatment were included between January 2018 and January 2019. Treatment started with three sonications on one side of the uterine fibroid. Subsequently, one ampoule of 1 mL carbetocin (100 µg/mL) was administered intravenously and treatment continued with three sonications on the other side of the uterine fibroid. We compared the intra-subject sonication efficiency, in terms of Energy Efficiency Factor (EEF), thermal dose volume and sonication time to ablate one cm
3 of fibroid tissue, before and after carbetocin administration. Adverse events that occurred within 30 min after carbetocin administration were recorded.
Results: Sonication efficiency improved after carbetocin administration as indicated by a significant decrease in EEF and sonication time (p = 0.006 and p = 0.001 respectively), and a significant increase in thermal dose volume reached (p = <0.001). Five women (16.7%) experienced temporary tachycardia, one women in combination with headache, within 30 min after carbetocin administration.Conclusion: Administration of the long-acting uterus stimulant carbetocin improved the MR-HIFU treatment intra-subject sonication efficiency in women with symptomatic uterine fibroids.
AB - Purpose: We investigated whether administration of the long-acting uterus stimulant carbetocin increased intra-subject sonication efficiency during Magnetic Resonance image guided High Intensity Focused Ultrasound (MR-HIFU) treatment of uterine fibroids.Method: In this prospective cohort study, thirty women with symptomatic uterine fibroids undergoing MR-HIFU treatment were included between January 2018 and January 2019. Treatment started with three sonications on one side of the uterine fibroid. Subsequently, one ampoule of 1 mL carbetocin (100 µg/mL) was administered intravenously and treatment continued with three sonications on the other side of the uterine fibroid. We compared the intra-subject sonication efficiency, in terms of Energy Efficiency Factor (EEF), thermal dose volume and sonication time to ablate one cm
3 of fibroid tissue, before and after carbetocin administration. Adverse events that occurred within 30 min after carbetocin administration were recorded.
Results: Sonication efficiency improved after carbetocin administration as indicated by a significant decrease in EEF and sonication time (p = 0.006 and p = 0.001 respectively), and a significant increase in thermal dose volume reached (p = <0.001). Five women (16.7%) experienced temporary tachycardia, one women in combination with headache, within 30 min after carbetocin administration.Conclusion: Administration of the long-acting uterus stimulant carbetocin improved the MR-HIFU treatment intra-subject sonication efficiency in women with symptomatic uterine fibroids.
KW - Efficiency
KW - High-intensity focused ultrasound ablation
KW - MR guided interventional procedures
KW - Myoma
KW - Uterine fibroids
KW - Uterus stimulant
UR - http://www.scopus.com/inward/record.url?scp=85126648561&partnerID=8YFLogxK
U2 - 10.1016/j.ejro.2022.100413
DO - 10.1016/j.ejro.2022.100413
M3 - Article
C2 - 35340827
SN - 2352-0477
VL - 9
SP - 1
EP - 8
JO - European journal of radiology open
JF - European journal of radiology open
M1 - 100413
ER -